| 1 |
Zhao Y, Deng Y, Jiang Y, Zheng W, Tan Y, Yang Z, Wang Z, Xu F, Cheng Z, Yuan L, Peng H. Case report: Targeting the PD-1 receptor and genetic mutations validated in primary histiocytic sarcoma with hemophagocytic lymphohistiocytosis. Front Immunol 2023;14. [DOI: 10.3389/fimmu.2023.1127599] [Reference Citation Analysis]
|
| 2 |
Zhang C, Wang L, Xu C, Xu H, Wu Y. Resistance mechanisms of immune checkpoint inhibition in lymphoma: Focusing on the tumor microenvironment. Front Pharmacol 2023;14. [DOI: 10.3389/fphar.2023.1079924] [Reference Citation Analysis]
|
| 3 |
Reyna Villasmil E. Anticuerpos inmunomoduladores en el tratamiento del cáncer. Repert Med Cir 2023;32:23-28. [DOI: 10.31260/repertmedcir.01217372.1361] [Reference Citation Analysis]
|
| 4 |
Wei N, Chen TP. [Recent research on chimeric antigen receptor T cells in children with refractory/relapsed acute lymphoblastic leukemia]. Zhongguo Dang Dai Er Ke Za Zhi 2023;25:210-6. [PMID: 36854700 DOI: 10.7499/j.issn.1008-8830.2210056] [Reference Citation Analysis]
|
| 5 |
Davoodi-Moghaddam Z, Jafari-Raddani F, Noori M, Bashash D. A systematic review and meta-analysis of immune checkpoint therapy in relapsed or refractory non-Hodgkin lymphoma; a friend or foe? Transl Oncol 2023;30:101636. [PMID: 36773442 DOI: 10.1016/j.tranon.2023.101636] [Reference Citation Analysis]
|
| 6 |
Cui Y, Leng C. A glycolysis-related gene signatures in diffuse large B-Cell lymphoma predicts prognosis and tumor immune microenvironment. Front Cell Dev Biol 2023;11:1070777. [PMID: 36755971 DOI: 10.3389/fcell.2023.1070777] [Reference Citation Analysis]
|
| 7 |
Hatic H, Hearld KR, Das D, Deshane J. Clinical Outcomes in COVID-19 Patients Treated with Immunotherapy. Cancers (Basel) 2022;14. [PMID: 36497435 DOI: 10.3390/cancers14235954] [Reference Citation Analysis]
|
| 8 |
Guo J, Cai Y, Wang Z, Xu J, Chen H, Zhang J, Xu X, Rao H, Tian S. Double/triple hit lymphoma in the gastrointestinal tract: clinicopathological features, PD-L1 expression and screening strategy. Mod Pathol 2022;35:1667-76. [PMID: 36088477 DOI: 10.1038/s41379-022-01150-3] [Reference Citation Analysis]
|
| 9 |
Guo H, Yang J, Wang H, Liu X, Liu Y, Zhou K. Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms. Front Immunol 2022;13:1017990. [DOI: 10.3389/fimmu.2022.1017990] [Reference Citation Analysis]
|
| 10 |
Li Z, Duan Y, Ke Q, Wang M, Cen H, Zhu X. Gene set-based identification of two immune subtypes of diffuse large B cell lymphoma for guiding immune checkpoint blocking therapy. Front Genet 2022;13:1000460. [DOI: 10.3389/fgene.2022.1000460] [Reference Citation Analysis]
|
| 11 |
Maharaj K, Uriepero A, Sahakian E, Pinilla-ibarz J. Regulatory T cells (Tregs) in lymphoid malignancies and the impact of novel therapies. Front Immunol 2022;13:943354. [DOI: 10.3389/fimmu.2022.943354] [Reference Citation Analysis]
|
| 12 |
Abdulla M, Hollander P, Lindskog C, Sundström C, Enblad G, Saft L, Amini RM. Outcome in PCNSL patients and its association with PD-L1+ leukocytes in the tumor microenvironment. Acta Oncol 2022;:1-6. [PMID: 35621149 DOI: 10.1080/0284186X.2022.2075239] [Reference Citation Analysis]
|
| 13 |
Xie D, Jin X, Sun R, Zhang M, Wang J, Xiong X, Zhang X, Zhao M. Relapse Mechanism and Treatment Strategy After Chimeric Antigen Receptor T-Cell Therapy in Treating B-Cell Hematological Malignancies. Technol Cancer Res Treat 2022;21:15330338221118413. [PMID: 35989682 DOI: 10.1177/15330338221118413] [Reference Citation Analysis]
|
| 14 |
Matsushita M. Novel Treatment Strategies Utilizing Immune Reactions against Chronic Myelogenous Leukemia Stem Cells. Cancers (Basel) 2021;13:5435. [PMID: 34771599 DOI: 10.3390/cancers13215435] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
